As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

The EC has conditionally approved MSD's Welireg as a single agent for the treatment of adults with VHL disease and advanced ...

Product sales for the vaccine specialist Valneva reached €170m despite slow US sales of its chikungunya vaccine.

The US FDA has granted fast track designation to Rznomics' RZ-001 for the treatment of hepatocellular carcinoma (HCC).

Oncology studies present unique challenges when it comes to participant treatment, resupply, and study management.

HMRI has signed a memorandum of understanding (MoU) with Novartis Australia for expediting medical research to drive healthcare projects.

Two of Bambusa’s bispecific antibody candidates for immunological and inflammatory disorders are set to enter the clinic in ...

Bavarian Nordic sets up a bout with Valneva’s Ixchiq, the former’s Vimkunya already having an edge in population reach.

Ono Pharmaceutical has secured approval from the US Food and Drug Administration (FDA) for its kinase inhibitor Romvimza ...

Innate Pharma has gained breakthrough therapy designation for lacutamab to treat adults with relapsed or refractory Sézary ...

Moderna has reported revenue of $1bn for the fourth quarter (Q4) of 2024, a sharp decline from $2.8bn in the same quarter in ...

New EU regulations aim to speed up health technology assessments (HTAs), but the pharma industry raises logistical concerns.